| Kim Michelle Zweifler, PHD | |
|
8000 W Judge Perez Dr, Chalmette, LA 70043-1668 | |
| (504) 826-9600 | |
| Not Available |
| Full Name | Kim Michelle Zweifler |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 28 Years |
| Location | 8000 W Judge Perez Dr, Chalmette, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376769232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 886 (Alabama) | Secondary |
| 103TC0700X | Psychologist - Clinical | 1420 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
How many people will die from tobacco use in developed countries in 2030?
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
OIST researcher uses a computational approach in identifying proteins that will interact with potential drugs to speed up the process of drug discovery.
› Verified 3 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
How many people will die from tobacco use in developed countries in 2030?
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
OIST researcher uses a computational approach in identifying proteins that will interact with potential drugs to speed up the process of drug discovery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kim Michelle Zweifler, PHD 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Kim Michelle Zweifler, PHD 8000 W Judge Perez Dr, Chalmette, LA 70043-1668 Ph: (504) 826-9600 |
News Archive
How many people will die from tobacco use in developed countries in 2030?
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
OIST researcher uses a computational approach in identifying proteins that will interact with potential drugs to speed up the process of drug discovery.
› Verified 3 days ago
Edwina D Frank, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 8101 W Judge Perez Dr, Chalmette, LA 70043 Phone: 504-278-7401 Fax: 504-278-7475 |